Pregnancy outcomes in unselected singleton pregnant women with an increased risk of first-trimester Down's syndrome

Acta Obstetricia et Gynecologica Scandinavica

Volumn 83, Issue 12, 2004, Pages 1130-1134

  Liu, Silvia So Aei ^a   Lee, Fa Kung ^a   Lee, Jia Ling ^a   Tsai, Ming Song ^a   Cheongi, Mei Leng ^a   She, Bo Quing ^a   Chen, Su Chee ^a  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Down's syndrome screening; First trimester combined test; Pregnancy outcomes

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; FETUS; FETUS DEATH; FETUS ECHOGRAPHY; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; KARYOTYPE; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL HYPERTENSION; PLACENTA PREVIA; PREGNANCY; PREGNANCY COMPLICATION; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL SCREENING; PRIORITY JOURNAL; SINGLETON PREGNANCY; SPONTANEOUS ABORTION;

ADULT; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; DOWN SYNDROME; FEMALE; HUMANS; KARYOTYPING; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, PRENATAL;

EID: 10344234723     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2004.00425.x     Document Type: Article

References (33)

1. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997; 17: 821-9.
2. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998; 338: 955-61.
3. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341: 461-7.
4. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-7.
5. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000; 96: 207-13.
6. Spencer K. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A. Br J Obstet Gynecol 2001; 108: 1043-6.
7. Tsai MS, Huang YY, Hwa KY, Cheng CC, Lee FK. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy- associated plasma protein A for first-trimester Down's syndrome screening. J Formos Med Assoc 2001; 100: 319-25.
8. Spencer K. Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry. Prenat Diagn 2002; 22: 244-6.
9. Cuckle HS, van Lith JM. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999; 19: 505-12.
10. Johnson MR, Riddle AF, Grudzinskas JG, Sharma V, Collins WP, Nicolaides KH. Reduced circulating placental protein concentrations during the first trimester are associated with preterm labour and low birth weight. Hum Reprod 1993; 8: 1942-7.
11. Ogle R, Jauniaux E, Pahal GS, Dell E, Sheldrake A, Rodeck C. Serum screening for Down syndrome and adverse pregnancy outcomes: a case-controlled study. Prenat Diagn 2000; 20: 96-9.
12. Ong CYT, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. Br J Obstet Gynecol 2000; 107: 1265-70.
13. Michailidis GD, Economides DL. Nuchal translucency and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 2001; 17: 102-5.
14. Smith GCS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002; 87: 1762-7.
15. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 2002; 22: 778-82.
16. Tsai MS, Lee FK, Cheng CC, Hwa KY, Cheong ML, She BQ. Association between fetal nuchal translucency thickness in first trimester and subsequent gestational hypertension and preeclampsia. Prenat Diagn 2002; 22: 747-51.
17. Roccella EJ. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183 (Suppl. 1): S1-22.
18. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T et al. Maternal serum screening for Down's syndrome in early pregnancy. Br Med J 1988; 297: 883-7.
19. Moertel CA, Stupca PJ, Dewald GW. Pseudomosaicism, true mosaicism, and maternal cell contamination in amniotic fluid processed with in situ culture and robotic harvesting. Prenat Diagn 1992; 12: 671-83.
20. Hsieh TT, Hung TH, Hsu JJ, Shau WY, Su CW, Hsieh FJ. Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population. Obstet Gynecol 1997; 89: 937-40.
21. Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 2000; 20: 652-6.
22. Kowalczyk TD, Cabaniss ML, Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 1998; 91: 396-400.
23. Leporrier N, Herrou M, Morello R, Leymarie P. Fetuses with Down's syndrome detected by prenatal screening are more likely to abort spontaneously than fetuses with Down's syndrome not detected by prenatal screening. Br J Obstet Gynecol 2003; 110: 18-21.
24. McLean M, Bisits A, Davies J, Walters W, Hackshaw A, De Voss K et al. Predicting risk of preterm delivery by second-trimester measurement of maternal plasma corticotropin-releasing hormone and α-fetoprotein concentrations. Am J Obstet Gynecol 1999; 181: 207-15.
25. Hsu CD, Chan DW, Iriye B, Johnson TRB, Hong SF, Repke JT. Elevated serum human chorionic gonadotropin as evidence of secretary response in severe preeclampsia. Am J Obstet Gynecol 1994; 170: 1135-8.
26. Adekunle O, Gopee A, El-Sayed M, Thilaganathan B. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. Br J Radiol 1999; 72: 457-60.
27. Simpson JM, Sharland GK. Nuchal translucency and congenital heart defects: heart failure or not? Ultrasound Obstet Gynecol 2000; 16: 30-6.
28. Nicolaides KH, Heath V, Cicero S. Increased fetal nuchal translucency at 11-14 weeks [Review]. Prenat Diagn 2002; 22: 308-35.
29. Brambati B, Macintosh MCM, Teisner B, Maguiness S, Shrimanker K, Lanzani A et al. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. Br J Obstet Gynecol 1993; 100: 324-6.
30. Smith GCS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early-pregnancy origins of low birth weight. Nature 2002; 417: 916.
31. Morssink LP, Kornman LH, Hallahan TW, Kloosterman MD, Beekhuis JR, De Wolf BTHM et al. Maternal serum levels of free β-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 1998; 18: 147-52.
32. Bonno M, Oxvig C, Kephart GM, Wagner JM, Kristensen T, Sottrup-Jenan et al. Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. Lab Invest, 1994; 71: 560-6.
33. Kniss DA, Shubert PJ, Zimmerman PD, Landen MB, Gabbe SG. Insulinlike growth factors. Their regulation of glucose and amino acid transport in placental trophoblasts isolated from first-trimester chorionic villi. J Reprod Med 1994; 39: 249-56.